Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Steven M. Paul sold 30,000 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $130.00, for a total transaction of $3,900,000.00. Following the completion of the sale, the director now owns 31,000 shares of the company’s stock, valued at $4,030,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ:ALNY opened at $133.99 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $65.81 and a 12-month high of $134.51. The company has a quick ratio of 5.22, a current ratio of 5.38 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $14.66 billion, a PE ratio of -16.46 and a beta of 2.47. The firm has a 50-day moving average price of $118.69 and a 200 day moving average price of $97.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported ($2.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.25) by ($0.22). Alnylam Pharmaceuticals had a negative return on equity of 54.13% and a negative net margin of 403.24%. The business had revenue of $71.70 million during the quarter, compared to analyst estimates of $71.45 million. During the same period last year, the company earned ($1.82) EPS. The business’s revenue for the quarter was up 241.4% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.14 EPS for the current year.
Large investors have recently bought and sold shares of the stock. Livforsakringsbolaget Skandia Omsesidigt raised its position in Alnylam Pharmaceuticals by 62.5% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,300 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 500 shares in the last quarter. State Street Corp raised its position in Alnylam Pharmaceuticals by 3.7% in the third quarter. State Street Corp now owns 3,001,157 shares of the biopharmaceutical company’s stock worth $241,353,000 after purchasing an additional 108,000 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in Alnylam Pharmaceuticals by 29.3% in the third quarter. Parametric Portfolio Associates LLC now owns 197,388 shares of the biopharmaceutical company’s stock worth $15,874,000 after purchasing an additional 44,701 shares in the last quarter. Andra AP fonden acquired a new position in Alnylam Pharmaceuticals in the third quarter worth about $225,000. Finally, Millennium Management LLC raised its position in Alnylam Pharmaceuticals by 41.0% in the third quarter. Millennium Management LLC now owns 217,224 shares of the biopharmaceutical company’s stock worth $17,469,000 after purchasing an additional 63,166 shares in the last quarter. 95.75% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have issued reports on ALNY. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $98.00 price target for the company. in a report on Tuesday, November 19th. Nomura upped their price target on shares of Alnylam Pharmaceuticals from $62.00 to $75.00 and gave the company a “reduce” rating in a report on Tuesday. Evercore ISI began coverage on shares of Alnylam Pharmaceuticals in a report on Friday, February 7th. They set a “buy” rating and a $145.00 price target for the company. Oppenheimer initiated coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. They set an “outperform” rating and a $128.00 price target for the company. Finally, Barclays increased their target price on shares of Alnylam Pharmaceuticals from $125.00 to $131.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $124.17.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Read More: Correction
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.